Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO highlights: Bevacizumab for relapsed ovarian cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.07.18
Views: 633

Prof Jonathan Ledermann - University College London Hospitals, London, UK

Prof Ledermann speaks with ecancer at BCGS 2018 about results from ASCO 2018 showing improved response rate and PFS for platinum-refractory patients who received second-line therapy with additional bevacizumab.

He considers what this means for global practice, noting the lack of availability in the UK for some patients, and how the activity in platinum-sensitive patients correlates to platinum-recurrent patients.

Prof Ledermann also spoke with ecancer about the results of the KEYNOTE100 trial, here.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation